After clinical trials demonstrated its safety and efficacy, the US Food and Drug Administration approved Simponi Aria for 2 new indications in adult patients.
The US Food and Drug Administration recently approved once-daily extended-release tablets for the management of 2 peripheral neuropathic pain conditions.
The US Food and Drug Administration recently approved once-daily extended-release tablets for the management of 2 peripheral neuropathic pain conditions.
The US Food and Drug Administration recently approved once-daily extended-release tablets for the management of 2 peripheral neuropathic pain conditions.
After results from a clinical trial demonstrated its safety and efficacy, the US Food and Drug Administration recently approved the first and only extended-release intra-articular injection for patients...
The FDA has approved a generic option for the treatment of patients with relapsing forms of multiple sclerosis. For details, including dosage and common adverse effects, read more.
The FDA has approved a generic option for the treatment of patients with relapsing forms of multiple sclerosis. For details, including dosage and common adverse effects, read more.
